StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Nurtec ODT / Vydura (rimegepant by Quarter

Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — Worldwide operational (constant-currency) YoY (%) (%)

QuarterlyAnnual

Pfizer Nurtec ODT / Vydura (rimegepant: 17.0% in Q2 2026, up 16.0 pts from a year earlier.

Latest, Q2 2026
17.0%
Period ended Jun 28, 2026
Change on a year earlier
+16.0 pts
1.0% in Q2 2025
History
11 quarters
Since Q4 2023
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

“|| Nurtec ODT/Vydura | 421 | 359 | 18% | 17% | 365 | 333 | 10% | 56 | 25 | * | *”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — Worldwide operational (constant-currency) YoY (%) (%)Year on yearSource
Q2 2026Jun 28, 202617.0%+16.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 202641.0%+1.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 20253.0%-36.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 202522.0%-23.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 20251.0%-43.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2025Mar 30, 202540.0%+33.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2024Dec 31, 202439.0%+6.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2024Sep 29, 202445.0%–Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2024Jun 30, 202444.0%–Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 20247.0%–Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2023Dec 31, 202333.0%–Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗

Cite this data

StockData. (2026). Pfizer Nurtec ODT / Vydura (rimegepant (%), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/nurtec-oper-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.